ZA200408573B - Treatment and prevention of pulmonary conditions. - Google Patents

Treatment and prevention of pulmonary conditions. Download PDF

Info

Publication number
ZA200408573B
ZA200408573B ZA200408573A ZA200408573A ZA200408573B ZA 200408573 B ZA200408573 B ZA 200408573B ZA 200408573 A ZA200408573 A ZA 200408573A ZA 200408573 A ZA200408573 A ZA 200408573A ZA 200408573 B ZA200408573 B ZA 200408573B
Authority
ZA
South Africa
Prior art keywords
seq
composition
inhibitor
amino acid
acid
Prior art date
Application number
ZA200408573A
Other languages
English (en)
Inventor
Charles G Cochrane
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of ZA200408573B publication Critical patent/ZA200408573B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200408573A 2002-04-25 2004-10-22 Treatment and prevention of pulmonary conditions. ZA200408573B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37596802P 2002-04-25 2002-04-25

Publications (1)

Publication Number Publication Date
ZA200408573B true ZA200408573B (en) 2006-03-29

Family

ID=29270737

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200408573A ZA200408573B (en) 2002-04-25 2004-10-22 Treatment and prevention of pulmonary conditions.

Country Status (13)

Country Link
US (2) US7863241B2 (enExample)
EP (1) EP1558273B1 (enExample)
JP (2) JP4651946B2 (enExample)
KR (2) KR101036058B1 (enExample)
CN (1) CN1838964A (enExample)
AT (1) ATE520411T1 (enExample)
AU (1) AU2003223718B2 (enExample)
CA (1) CA2483102C (enExample)
IL (2) IL164795A0 (enExample)
MX (1) MXPA04010560A (enExample)
NZ (1) NZ536796A (enExample)
WO (1) WO2003090682A2 (enExample)
ZA (1) ZA200408573B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223718B2 (en) 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
AU2004296206A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
WO2005073246A2 (en) * 2004-01-20 2005-08-11 Discovery Laboratories, Inc. Method for preparing kl4 lung surfactant
WO2005087249A1 (ja) * 2004-03-11 2005-09-22 Kurume University プロテアーゼ阻害剤及び疾患の予防又は治療剤
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
CA2570261C (en) 2004-07-08 2014-06-10 Pneumrx, Inc. Pleural effusion treatment device, method and material
KR101241434B1 (ko) * 2004-09-10 2013-03-12 파마오리진 에이피에스 국소 기관, 기관지 또는 폐포의 출혈 또는 객혈의 치료방법
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
CN101094651B (zh) * 2004-12-30 2011-03-09 多贝尔有限公司 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法
GB0510463D0 (en) * 2005-05-23 2005-06-29 Britania Pharmaceuticals Ltd Improvements in or relating to organic materials
CN101262880A (zh) * 2005-06-24 2008-09-10 德拉格雷丘尔公司 在影响呼吸道的炎症病状中气道施用组织因子途径抑制物
WO2007005672A2 (en) * 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
EP2142196A4 (en) 2007-03-29 2010-06-30 Nat Jewish Health SURFACTANTLIPIDS, COMPOSITIONS AND THEIR USE
EP1997502A1 (en) * 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties
EP2170270B1 (en) * 2007-06-05 2016-01-13 Paka Pulmonary Pharmaceuticals, Inc. Compositions for delivering medicaments into the lungs, uses thereof
EP2227085A4 (en) * 2007-12-06 2013-10-09 Berg Pharma Llc INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY
GB0724772D0 (en) * 2007-12-19 2008-01-30 Ucl Business Plc Carrier
EP2370068A4 (en) 2008-12-10 2015-09-23 Paka Pulmonary Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR DELIVERING MEDICAMENTS TO THE LUNG
CN102300582A (zh) 2009-01-30 2011-12-28 阿尔法贝塔公司 用于治疗阿尔茨海默病的化合物和方法
US8434479B2 (en) 2009-02-27 2013-05-07 Covidien Lp Flow rate compensation for transient thermal response of hot-wire anemometers
JP5622728B2 (ja) * 2009-08-06 2014-11-12 一般財団法人化学及血清療法研究所 咳嗽抑制効果を持つ血漿タンパク質
EP2308489B1 (en) 2009-10-05 2014-01-01 Nutri-Fit GmbH & Co. KG Compositions for use in treating or preventing metabolic stress-induced lung injury and methods for increasing physical capacity of mammalian livestock
NZ599783A (en) * 2009-11-03 2013-10-25 Grifols Therapeutics Inc Composition and use for alpha-1 proteinase inhibitor
KR101567901B1 (ko) 2009-11-24 2015-11-10 그리폴스 테라퓨틱스 인코포레이티드 동결건조 방법, 조성물, 및 키트
GB201003559D0 (en) * 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
US11400058B2 (en) 2010-03-12 2022-08-02 Berg Llc Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof
WO2011162655A1 (en) 2010-06-24 2011-12-29 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
CN101897720B (zh) * 2010-07-27 2015-09-09 北京华禧联合科技发展有限公司 一种治疗呼吸道疾病的药物组合物
WO2012061750A2 (en) * 2010-11-04 2012-05-10 The Board Of Regents Of The University Of Oklahoma Peptide compositions that downregulate tlr-4 signaling pathway and methods of producing and using same
US20130184202A1 (en) * 2011-02-08 2013-07-18 Changjiang Guo Peptide Inhibitors and Methods of Use Thereof
EP2694977B1 (en) 2011-04-05 2016-06-29 Alphabeta AB Amyloidosis target useful in methods of screening of compounds
ES2711670T3 (es) 2011-04-12 2019-05-06 Moerae Matrix Inc Composiciones y métodos para la prevención o tratamiento de la fibrosis pulmonar
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EA201490047A1 (ru) 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
US9089657B2 (en) 2011-10-31 2015-07-28 Covidien Lp Methods and systems for gating user initiated increases in oxygen concentration during ventilation
WO2013188016A2 (en) * 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
CN105745223A (zh) 2013-09-18 2016-07-06 詹姆斯库克大学 修饰的抗炎蛋白及使用方法
AU2014324093A1 (en) * 2013-09-18 2016-04-28 James Cook University Anti-inflammatory proteins and methods of use
WO2015061412A1 (en) * 2013-10-22 2015-04-30 The Scripps Research Institute Methods and compositions for promoting bronchioli dilatation
WO2016030323A1 (en) * 2014-08-26 2016-03-03 Proteo Biotech Ag Use of elafin for disorders associated with elastase independent increase in troponin
US10568846B2 (en) 2015-04-27 2020-02-25 Omniactive Health Technologies Limited Betacryptoxanthin compositions, processes for preparation and uses thereof
US10239847B1 (en) 2016-03-03 2019-03-26 Cellactin Method for 2-oxothiazolidine-4-carboxylic acid for cellular glutathione
EP3512539A4 (en) * 2016-09-13 2020-07-29 Prothera Biologics, Inc. METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS
AU2018241248B2 (en) * 2017-03-31 2025-01-23 Ena Respiratory Pty Ltd Treatment of respiratory infection with a TLR2 agonist
EP3727353A4 (en) * 2017-12-21 2021-10-13 Civitas Therapeutics, Inc. SURFACTANT FORMULATIONS FOR INHALATION
CN112654344A (zh) * 2018-04-17 2021-04-13 板层小体生物医学有限公司 抗纤维化组合物
JP7483684B2 (ja) * 2018-08-17 2024-05-15 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 急性肺損傷の処置のための組成物および方法
AU2019361193B2 (en) 2018-10-19 2025-06-26 Ohio State Innovation Foundation Nanocarriers for lung inflammation therapy
CA3117213A1 (en) * 2018-10-23 2020-04-30 George Edward Hoag Composition and method for treating the lungs
AU2019370363B2 (en) * 2018-10-30 2025-07-10 University Of Florida Research Foundation, Incorporated Amino acid compositions and methods for treating cystic fibrosis
CA3145702A1 (en) * 2019-08-01 2021-02-04 Philip A. Pemberton Oxidation-resistant serpins
KR102276935B1 (ko) * 2020-02-06 2021-07-12 한양대학교 산학협력단 신규한 비올라크산틴 고생산 클로렐라 불가리스 균주 및 이로부터 비올라크산틴을 생산하는 방법
CN115379828A (zh) * 2020-04-08 2022-11-22 代表亚利桑那大学的亚利桑那校董会 用于治疗和预防肺病的组合物和方法
CN115245559A (zh) * 2021-04-25 2022-10-28 上海萨美细胞技术有限公司 一种用于治疗肺损伤的药物
WO2024097169A1 (en) * 2022-11-01 2024-05-10 National Jewish Health Treatment of coronavirus infections with antimicrobial phospholipid compositions
CN116421704A (zh) * 2023-02-20 2023-07-14 成都佩德生物医药有限公司 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物
CN120000688B (zh) * 2025-04-16 2025-08-05 山东杰凯生物科技有限公司 基于干细胞外囊泡的雾化吸入组合物及其制备方法、应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57144224A (en) * 1981-03-02 1982-09-06 Mochida Pharmaceut Co Ltd Remedy for respiratory dieseases
US4916117A (en) * 1986-12-24 1990-04-10 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5260273A (en) * 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US5164369A (en) * 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
WO1991000871A1 (en) * 1989-07-11 1991-01-24 Genentech, Inc. Surfactant compositions and methods
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
ES2107048T3 (es) * 1992-07-31 1997-11-16 Merrell Pharma Inc Tensioactivos pulmonares peptidicos sinteticos con antioxidantes covalentemente unidos.
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5301644A (en) 1993-06-16 1994-04-12 Kohler Co. Fuel shut-off mechanism for internal combustion engines
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
EP0763055B1 (en) * 1994-06-02 1999-11-03 Merrell Pharmaceuticals Inc. Perfluoroalkyl ketone inhibitors of elastase and processes for making the same
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5878912A (en) 1995-12-26 1999-03-09 Stein; Myron Duct disinfecting method and apparatus
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
WO1998029098A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US6051257A (en) 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
JP3796340B2 (ja) * 1997-11-18 2006-07-12 株式会社ノエビア セリンプロテアーゼ阻害剤
JPH11147832A (ja) * 1997-11-18 1999-06-02 Noevir Co Ltd 好中球エラスターゼ阻害剤
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US5883084A (en) * 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
US6223455B1 (en) 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
EP1216052A1 (en) 1999-09-16 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
WO2001048231A2 (en) * 1999-12-28 2001-07-05 Novartis Ag Method of achieving persistent transgene expression
AU2908501A (en) * 2000-01-06 2001-07-16 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
AU2003223718B2 (en) 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
US6819898B2 (en) * 2002-11-22 2004-11-16 Kabushiki Kaisha Toshiba Image forming apparatus including stopping member and backstop member to stop rotation of revolver type developing unit

Also Published As

Publication number Publication date
US7863241B2 (en) 2011-01-04
JP2005529885A (ja) 2005-10-06
JP2011001383A (ja) 2011-01-06
CA2483102A1 (en) 2003-11-06
AU2003223718C1 (en) 2003-11-10
KR101036058B1 (ko) 2011-05-19
JP4651946B2 (ja) 2011-03-16
EP1558273B1 (en) 2011-08-17
NZ536796A (en) 2007-03-30
EP1558273A2 (en) 2005-08-03
US20120189602A1 (en) 2012-07-26
EP1558273A4 (en) 2008-07-16
WO2003090682A3 (en) 2004-09-16
AU2003223718A1 (en) 2003-11-10
CA2483102C (en) 2013-06-18
WO2003090682A2 (en) 2003-11-06
ATE520411T1 (de) 2011-09-15
IL164795A (en) 2011-02-28
MXPA04010560A (es) 2005-08-15
AU2003223718B2 (en) 2007-08-16
KR20110017465A (ko) 2011-02-21
KR20050019073A (ko) 2005-02-28
US20050070477A1 (en) 2005-03-31
IL164795A0 (en) 2005-12-18
CN1838964A (zh) 2006-09-27

Similar Documents

Publication Publication Date Title
AU2003223718B2 (en) Treatment and prevention of pulmonary conditions
JP2005529885A5 (enExample)
EP1833503B1 (en) Pulmonary surfactant formulations
JP5405307B2 (ja) 改善された性質を有する再構成サーファクタント
US20070129297A1 (en) Treatment and prevention of asthma
JP2013177422A (ja) サーファクタント処置療法
WO2007005672A2 (en) Treatment and prevention of respiratory diseases and conditions
WO2015061412A1 (en) Methods and compositions for promoting bronchioli dilatation
HK1109077B (en) Pulmonary surfactant formulations
HK1109078B (en) Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia